CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been assigned an average rating of “Hold” from the nineteen brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $75.63.
A number of equities analysts have issued reports on the company. Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Barclays cut their price target on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 6th. Chardan Capital cut their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Finally, Stifel Nicolaus dropped their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th.
Institutional Inflows and Outflows
CRISPR Therapeutics Price Performance
Shares of NASDAQ CRSP opened at $46.74 on Thursday. The stock has a market capitalization of $3.97 billion, a PE ratio of -17.18 and a beta of 1.68. CRISPR Therapeutics has a one year low of $37.55 and a one year high of $91.10. The business’s fifty day moving average price is $50.23 and its 200-day moving average price is $56.60.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. During the same quarter last year, the firm earned ($0.98) EPS. The firm’s quarterly revenue was down 99.3% on a year-over-year basis. As a group, equities analysts expect that CRISPR Therapeutics will post -5.6 EPS for the current fiscal year.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
See Also
- Five stocks we like better than CRISPR Therapeutics
- Using the MarketBeat Stock Split Calculator
- The Average 401k Balance by Age Explained
- Ride Out The Recession With These Dividend KingsĀ
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Are Penny Stocks a Good Fit for Your Portfolio?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.